Nihar Desai
Cardiovascular Disease · New Haven, CTNPI 1700930120
Payments from drug & device makers
Across 1,248 payments — averaging $2574.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1.5M
- Boehringer Ingelheim$1.3M
- Vifor Pharma, Inc.$117K
- AstraZeneca$66K
- Novartis$66K
- Bayer$48K
- plus $132K from 20 others
Across 19 payments — averaging $3401.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$56K
- Amgen$8K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 742 | $1,530,312 |
| Boehringer Ingelheim | 240 | $1,253,740 |
| Vifor Pharma, Inc. | 24 | $116,707 |
| AstraZeneca | 70 | $66,038 |
| Novartis | 46 | $65,895 |
| Bayer | 31 | $47,812 |
| Merck | 21 | $20,337 |
| Eli Lilly | 8 | $19,268 |
| Vifor (international) Ltd. | 10 | $18,307 |
| Vifor Fresenius Medical Care Renal Pharma Ltd. | 5 | $13,053 |
| Pharmacosmos Therapeutics Inc. | 6 | $12,892 |
| Boehringer Ingelheim International GmbH | 12 | $10,171 |
| Heartflow, Inc. | 5 | $6,860 |
| CSL Behring | 3 | $6,802 |
| Novo Nordisk AS | 1 | $5,000 |
| Regeneron Healthcare Solutions, Inc. | 4 | $4,506 |
| Lilly USA, LLC | 2 | $4,214 |
| Sanofi-aventis U.S. LLC | 1 | $2,864 |
| Abbott | 7 | $2,636 |
| Sanofi Pasteur Inc. | 1 | $2,462 |
| Amarin Pharma, Inc. | 1 | $1,800 |
| Johnson & Johnson | 4 | $431 |
| Janssen Scientific Affairs, LLC | 1 | $120 |
| Biotronik Inc. | 1 | $115 |
| Novo Nordisk | 1 | $104 |
| Servier Pharmaceuticals LLC | 1 | $31 |
How this compares
$3,212,477 in reported general payments places this provider in the 95th percentile of 415 cardiovascular disease providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in New Haven
- Harlan KrumholzNew Haven$4M
- Jeffery TestaniNew Haven$3.4M
- John ForrestNew Haven$1.2M
- Hyung ChunNew Haven$1.1M
- Rohan KheraNew Haven$930K
- Carlos Mena-HurtadoNew Haven$665K
- John StendahlNew Haven$419K
- Tariq AhmadNew Haven$317K
- Rachel LampertNew Haven$310K
- Daniel JacobyNew Haven$293K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.